TPO/c-MPL通路在急性髓系白血病中的研究现况  

Research Status of TPO/c-MPL Signaling Pathway in Acute Myeloid Leukemia——Review

作　　者：王楠 朱海燕 WANG Nan;ZHU Hai-Yan(Department of Hematology,The First Medical Center,Chinese PLA General Hospital,Beijing 100853,China)

机构地区：[1]中国人民解放军总医院第一医学中心血液科,北京100853

出　　处：《中国实验血液学杂志》2021年第4期1351-1354,共4页Journal of Experimental Hematology

摘　　要：血小板生成素(TPO)作用于其受体c-MPL可激活下游通路刺激造血细胞的增殖,诱导巨核细胞生成。近年来,有国内外研究证实,TPO/c-MPL通路还在白血病干细胞的自我更新和静止中发挥重要作用,在急性髓系白血病中的表达还提示化疗耐药和预后不良。本文结合目前研究进展,就TPO/c-MPL通路在急性髓系白血病患者中的表达、化疗耐药和预后以及TPO/c-MPL受体激动剂在急性髓系白血病中应用的最新研究进展作一综述。Thrombopoietin(TPO) can activate hematopoietic cell proliferation by its receptor c-MPL mediated downstream pathways and induce the generation of megakaryocyte. In recent years, domestic and foreign researches have confirmed that TPO/c-MPL pathway also plays an important role in the self-renewal and quiescence of leukemia stem cell, and its expression in acute myeloid leukemia(AML) also indicates the chemotherapy resistance and poor prognosis.In this article, the research progress of the roles of TPO/c-MPL pathway in chemotherapy resistance, prognosis of AML patients, and the application of TPO/c-MPL receptor agonists in AML were summarized briefly.

关 键 词：急性髓系白血病 血小板生成素 C-MPL 化疗耐药 

分 类 号：R733.71[医药卫生—肿瘤]